Paper Details

  1. Home
  2. Paper Details

[Botulinum toxin type A in the prophylactic treatment of chronic migraine].

Author: GöbelH, HeinzeA

Journal ArticleAn article published in an academic or professional journal that reports original research or scholarly analysis.
Multicenter StudyResearch conducted in collaboration with multiple research institutions. It aims to collect a wide range of data and obtain more generalizable results.
Randomized Controlled TrialA clinical trial that randomly assigns participants to treatment and control groups to evaluate the effects of an intervention.

Overview

While chronic migraine is less common than other types of migraine, it has a significant impact on patients. Previously, there was no approved medication for preventing chronic migraines. However, a new treatment using botulinum toxin type A (Botox) has been found to be effective and well-tolerated in clinical trials. Botox has been approved for treating chronic migraine in England and is currently awaiting approval in Germany.
Paper Details　
Original Abstract of the Article :
Since the second edition of the International classification of headache disorders (ICDH-II 2004), chronic migraine has been listed amongst migraine complications. Compared to episodic migraine the prevalence of chronic migraine is low, its impact, however, significant. Until recently no prophylacti...See full text at original site
Dr.Camel IconDr.Camel's Paper Summary Blogラクダ博士について

ラクダ博士は、Health Journal が論文の内容を分かりやすく解説するために作成した架空のキャラクターです。
難解な医学論文を、専門知識のない方にも理解しやすいように、噛み砕いて説明することを目指しています。

* ラクダ博士による解説は、あくまで論文の要点をまとめたものであり、原論文の完全な代替となるものではありません。詳細な内容については、必ず原論文をご参照ください。
* ラクダ博士は架空のキャラクターであり、実際の医学研究者や医療従事者とは一切関係がありません。
* 解説の内容は Health Journal が独自に解釈・作成したものであり、原論文の著者または出版社の見解を反映するものではありません。


引用元：
https://doi.org/10.1007/s00482-011-1084-6

データ提供：米国国立医学図書館（NLM）

Botulinum Toxin Type A: A New Era for Chronic Migraine Prophylaxis

The battle against chronic migraine is a long and arduous one. This research explores the potential of botulinum toxin type A as a prophylactic treatment for chronic migraine, a debilitating condition that significantly impacts quality of life. The study highlights the effectiveness of botulinum toxin type A in reducing migraine frequency and severity compared to placebo. These findings represent a significant breakthrough in the treatment of chronic migraine, offering a new and effective option for individuals seeking relief from this debilitating condition.

Botulinum Toxin Type A Shows Superiority in Chronic Migraine

The study's findings demonstrate the superiority of botulinum toxin type A over placebo in reducing migraine frequency and severity. This breakthrough provides a valuable tool for managing chronic migraine and significantly improving the quality of life for those suffering from this condition.

Managing Chronic Migraine: A Collaborative Approach

The complex nature of chronic migraine requires a multifaceted approach to management. This study highlights the potential of botulinum toxin type A as a prophylactic treatment option, adding to the growing arsenal of tools available for managing chronic migraine. As always, consulting with a healthcare professional is crucial for personalized diagnosis and treatment plans.

Dr. Camel's Conclusion

Just as a camel perseveres through the harsh desert, individuals with chronic migraine endure significant challenges. This study offers a ray of hope, showcasing the potential of botulinum toxin type A as a valuable tool for managing this debilitating condition. While further research is ongoing, the findings present a promising new avenue for relief and improved quality of life for those suffering from chronic migraine.

Date :
  1. Date Completed 2012-04-18
  2. Date Revised 2021-10-20
Further Info :

Pubmed ID

21938606

DOI: Digital Object Identifier

10.1007/s00482-011-1084-6

Related Literature

Article Analysis
・Effective treatment of migraine
SNS
PICO Info
in preparation
Languages

German

Positive IndicatorAn AI analysis index that serves as a benchmark for how positive the results of the study are. Note that it is a benchmark and requires careful interpretation and consideration of different perspectives.

This site uses cookies. Visit our privacy policy page or click the link in any footer for more information and to change your preferences.